Time to antibiotics and outcomes in cancer patients with febrile neutropenia

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Perron, Thomas ^a   Emara, Mohamed ^b   Ahmed, Shahid ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Febrile neutropenia; Hospital mortality; Length of stay; Outcome; Time to antibiotic

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; AGED; COMPLICATION; DRUG ADMINISTRATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; MIDDLE AGED; MORTALITY; NEOPLASM; REGRESSION ANALYSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TIME; TREATMENT OUTCOME; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899586260     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-162     Document Type: Article

References (19)

1. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JH, Wingard JR, Clin Infect Dis 2011 52 4 56 10.1093/cid/cir073 21258094
2. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH, Cancer 2006 106 2258 2266 10.1002/cncr.21847 16575919 (Pubitemid 43673249)
3. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, Avritscher EBC, Shih YT, Ensor J, Bekele BN, Gralla RJ, Talcott JA, Rolston K, J Clin Oncol 2008 26 606 611 10.1200/JCO.2007.13.8222 18235119 (Pubitemid 351264355)
4. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock-2008. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL, Intensive Care Med 2008 34 17 60 10.1007/s00134-007-0934-2 18058085
5. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KV, Ramsey SD, J Clin Oncol 2013 31 794 10.1200/JCO.2012.45.8661 23319691
6. Emergency department waiting times for patients with cancer with febrile neutropenia: a pilot study. Nirenberg A, Mulhearn L, Lin S, Larson E, Oncol Nurs Forum 2004 31 711 715 10.1188/04.ONF.711-715 15252427
7. Neutropenic fever: one institution's quality improvement project to decrease time from patient arrival to initiation of antibiotic therapy. Baltic T, Schlosser E, Bedell MK, Clin J Oncol Nurs 2002 6 337 340 12434465
8. Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit. Clarke RT, Warnick J, Stretton K, Littlewood TJ, Br J Haematol 2011 153 773 10.1111/j.1365-2141.2011.08693.x 21517822
9. Assessment and management of febrile neutropenia in emergency departments within a regional health authority-a benchmark analysis. Szwajcer D, Czaykowski P, Turner D, Curr Oncol 2011 16 280 284
10. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Klatersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J, J Clin Oncol 2000 18 3038 3051 10944139 (Pubitemid 30644129)
11. The Multinational Association for Supportive Care in Cancer (MASCC) risk index, http://www.qxmd.com/calculate-online/hematology/febrile-neutropenia-mascc
12. Implementation of an evidence-based order set to impact initial antibiotic time intervals in adult febrile neutropenia. Best JT, Frith K, Anderson F, Rapp CG, Rioux L, Ciccarello C, Oncol Nurs Forum 2011 38 661 668 10.1188/11.ONF.661-668 22037329
13. Improving timeliness of antibiotic delivery for patients with fever and suspected neutropenia in a pediatric emergency department. Volpe D, Harrison S, Damian F, Rachh P, Kahlon PS, Morrissey L, Mack J, Akenroye A, Stack AM, Pediatrics 2012 201 130
14. Identification of education and infrastructural barriers to prompt antibiotic delivery in febrile neutropenia: a quality improvement initiative. Burry E, Punnett A, Mehta A, Thull-Freedman J, Robinson L, Gupta S, Pediatr Blood Cancer 2012 59 431 435 10.1002/pbc.23418 22147665
15. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Klastersky J, Paesmans M, Support Care Cancer 2013 21 1487 1495 10.1007/s00520-013-1758-y 23443617
16. Elevated blood urea nitrogen is an independent risk factor of prolonged intensive care unit stay due to acute necrotizing pancreatitis. Faisst M, Wellner UF, Utzolino S, Hopt UT, Keck T, J Crit Care 2010 25 105 111 10.1016/j.jcrc.2009.02.002 19427764
17. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Prevention and treatment of cancer-related infections. Version 1 2012 http://www.nccn.org (Accessed on May 10, 2013)
18. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy? Klastersky J, J Antimicrob Chemother 2009 63 Suppl 1 14 i15 19372173
19. Survival in neutropenic patients with severe sepsis or septic shock. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, Lemiale V, Seguin A, Darmon M, Schlemmer B, Azoulay E, Crit Care Med 2012 40 43 10.1097/CCM.0b013e31822b50c2 21926615